RE:Moving ForwardI think the answer was provided Monday. There appears to be lots of $$ on table to do a whole bunch of things that we have been begging them to do for the last several years, but couldn't as they were surviving on a shoestring budget trying to get a first "real deal" out the door.
Now that there is significant attention on the scientific pipeline (Characterized by Linda Pullan as a disrtuptive tech), they have to rethink their positioning and growth strategy to become more relevant.
A full corporate strategy review with input from a Pharmaceutal industry expert is going to get this company positioned with everything they will need to pursue to get into mid-tier status. We want $3-5 dollars per share, well this is the only way. And it certainly implies there will be changes in the executive structure, so hallafriggenhula.
This is bang on.